KPTI News and Press, Karyopharm Therapeutics Inc. From 11/02/20

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Karyopharm Therapeutics Inc. 2020 Q3 - Results - Earnings Call Presentation

Karyopharm Therapeutics (KPTI): Q3 GAAP EPS of -$0.73 beats by $0.01.Revenue of $21.33M (+62.2% Y/Y) beats by $0.23M.2020 Outlook: Expects adj. R&D and SG&A expenses to be in the range of $240-260M.Press Release For further details see: Karyopharm Therapeutics EPS beats by ...

Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress -- Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma -- -- Third Quarter 2...

Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression-Free Survival in Patients with Unresectable Dedifferentiated Liposarcoma -- Twice-Weekly XPOVIO® (selinexor) Demonstrates a Statistically Significant Reduction in the Ris...

Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020 - Conference Call Scheduled for Monday, November 2, 2020, at 4:30 p.m. ET - PR Newswire NEWTON, Mass., Oct. 26, 2020 NEWTON, Mass. , Oct. 26, 2020 /PRNewswire/ -- Karyophar...

Karyopharm Therapeutics Selects MediSpend's Transparency Solution PR Newswire PORTSMOUTH, N.H., Oct. 20, 2020 PORTSMOUTH, N.H. , Oct. 20, 2020 /PRNewswire/ -- MediSpend announced that Karyopharm Therapeutics (NASDAQ: KPTI) selected MediSpend Tr...

WOBURN, Mass., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced the appointment of Tanya Lewis to its Board of Directors, effective as of No...

Karyopharm Therapeutics (KPTI) presents data from a Phase 2 clinical study evaluating low dose oral selinexor in hospitalized patients with severe COVID-19 at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for CO...

Karyopharm Announces Selinexor Clinical Data to be Presented at the International Society for Influenza and Other Respiratory Virus Diseases Antiviral Group Virtual Conference on Therapeutics for COVID-19 − Encouraging Anti-Viral and Anti-Inflammatory Activity Demonstrate...

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with this Read more ...